Coronavirus vaccine maker Moderna announces plans for phase 2 trial

Coronavirus Vaccine
  • Moderna, one of the first companies to start clinical trials on humans for a coronavirus vaccine, is looking to move to phase 2.
  • The mRNA-1273 vaccine candidate will be given to a larger cohort of patients in the second quarter of 2020 if regulators approve the next phase of the trial.
  • Moderna previously said that the vaccine might be ready for emergency use as soon as this fall.
  • Visit BGR's homepage for more stories.

Well over 70 coronavirus vaccine candidates are in development around the world in partnership with the World Health Organization (WHO), and several of them have reached the first phase of human testing. Vaccines are supposed to be both effective against COVID-19 infections and safe for those inoculated. That's why a vaccine can't be hurried to market, and why conservative estimates sit at 12 to 18 months.

Some of these candidates might be deployed earlier than that, as soon as this fall, assuming regulators allow emergency use for these drugs. One of them is Moderna's mRNA vaccine that already completed phase 1 of human trials. The company announced it's ready to move forward with the next step, with stage 2 set to include 600 patients.

Continue reading...

Today's Top Deals

  1. Amazon’s best-selling face masks are definitely going to sell out soon
  2. Today’s top deals: 3 types of face masks in stock now, deeper AirPods discount, $37 ANC headphones, protein bars, more
  3. Today’s best deals: Face masks back in stock, $9 wireless charger, $37 headphones, $18 Wi-Fi extender, $199 Nest, more

Trending Right Now:

  1. Walmart has a big sale you didn’t know about – here are the 10 best deals
  2. CDC says social distancing guidelines now apply to pets
  3. Fauci: US ‘could be in for a bad fall’ if coronavirus treatments don’t work

Coronavirus vaccine maker Moderna announces plans for phase 2 trial originally appeared on on Tue, 28 Apr 2020 at 22:08:12 EDT. Please see our terms for use of feeds.